Alberta Investment Management Corp lowered its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 0.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 86,300 shares of the medical research company’s stock after selling 200 shares during the quarter. Alberta Investment Management Corp’s holdings in Edwards Lifesciences were worth $18,978,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. TRUE Private Wealth Advisors purchased a new position in Edwards Lifesciences during the second quarter valued at approximately $26,000. Evolution Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the second quarter valued at approximately $29,000. M&R Capital Management Inc. purchased a new position in Edwards Lifesciences during the second quarter valued at approximately $29,000. Next Capital Management LLC lifted its holdings in Edwards Lifesciences by 297.7% during the second quarter. Next Capital Management LLC now owns 171 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 128 shares in the last quarter. Finally, Tarbox Family Office Inc. lifted its holdings in Edwards Lifesciences by 48.7% during the second quarter. Tarbox Family Office Inc. now owns 177 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 58 shares in the last quarter. 81.75% of the stock is currently owned by institutional investors and hedge funds.
In related news, VP Catherine M. Szyman sold 372 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $214.53, for a total value of $79,805.16. Following the sale, the vice president now owns 18,010 shares in the company, valued at $3,863,685.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 22,850 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $216.70, for a total transaction of $4,951,595.00. Following the completion of the sale, the chief executive officer now owns 95,770 shares in the company, valued at approximately $20,753,359. The disclosure for this sale can be found here. Insiders sold 137,253 shares of company stock worth $29,736,031 in the last 90 days. 1.63% of the stock is currently owned by company insiders.
EW stock opened at $228.86 on Friday. Edwards Lifesciences Corp has a one year low of $136.44 and a one year high of $238.37. The company’s fifty day moving average price is $222.41 and its 200-day moving average price is $199.73. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.48 and a current ratio of 3.38. The company has a market capitalization of $46.19 billion, a PE ratio of 48.69, a price-to-earnings-growth ratio of 2.80 and a beta of 0.84.
Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, October 23rd. The medical research company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.22 by $0.19. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The company’s quarterly revenue was up 20.7% compared to the same quarter last year. On average, research analysts predict that Edwards Lifesciences Corp will post 5.33 EPS for the current fiscal year.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Recommended Story: How to Track your Portfolio in Google Finance
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.